COVID-19 and Autoimmune/Autoinflammatory Rheumatic Disease Patients: Lessons Learned and Questions Anticipating Answers

Overview

Journal Mediterr J Rheumatol

Specialty Rheumatology

Date 2021 Dec 29

PMID 34964022

Citations 2

Authors

Athanasios-Dimitrios Bakasis

Haralampos M Moutsopoulos

Affiliations

Soon will be listed here.

Citing Articles

Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases.

Papagoras C, Zioga N, Papadopoulos V, Gerolymatou N, Kalavri E, Bounos C Clin Rheumatol. 2023; 42(12):3375-3385.

PMID: 37731083 PMC: 10640401. DOI: 10.1007/s10067-023-06769-4.

Clinical Features and Outcomes of Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease and Spondyloarthropathies.

Tozlu M, Dilek G, Unan M, Kamanli A, Tekeoglu I, Uslan M Turk J Gastroenterol. 2022; 33(9):751-759.

PMID: 36134550 PMC: 9524500. DOI: 10.5152/tjg.2022.22181.

References

Moutsopoulos H . A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine. J Autoimmun. 2021; 121:102649. PMC: 8088234. DOI: 10.1016/j.jaut.2021.102649. View

Bakasis A, Mavragani C, Boki K, Tzioufas A, Vlachoyiannopoulos P, Stergiou I . COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review. J Autoimmun. 2021; 123:102687. PMC: 8282479. DOI: 10.1016/j.jaut.2021.102687. View

Greenberg S . Infections in the immunocompromised rheumatologic patient. Crit Care Clin. 2002; 18(4):931-56. DOI: 10.1016/s0749-0704(02)00022-2. View

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

Hooks J, Moutsopoulos H, Geis S, Stahl N, Decker J, Notkins A . Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979; 301(1):5-8. DOI: 10.1056/NEJM197907053010102. View

Galani I, Rovina N, Lampropoulou V, Triantafyllia V, Manioudaki M, Pavlos E . Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat Immunol. 2020; 22(1):32-40. DOI: 10.1038/s41590-020-00840-x. View

Liu X, Shaw R, Stuart A, Greenland M, Aley P, Andrews N . Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021; 398(10303):856-869. PMC: 8346248. DOI: 10.1016/S0140-6736(21)01694-9. View

Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D . Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021; 80(10):1330-1338. DOI: 10.1136/annrheumdis-2021-220647. View

Wajnberg A, Amanat F, Firpo A, Altman D, Bailey M, Mansour M . Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020; 370(6521):1227-1230. PMC: 7810037. DOI: 10.1126/science.abd7728. View

10.

Mihai C, Dobrota R, Schroder M, Garaiman A, Jordan S, Becker M . COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis. 2020; 79(5):668-669. DOI: 10.1136/annrheumdis-2020-217442. View

11.

Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, Danila M, Gossec L . Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020; 79(7):859-866. PMC: 7299648. DOI: 10.1136/annrheumdis-2020-217871. View

12.

Moutsopoulos H . Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19. Ann Rheum Dis. 2020; 79(9):1253-1254. PMC: 7456551. DOI: 10.1136/annrheumdis-2020-217562. View

13.

Pelechas E, Drossou V, Voulgari P, Drosos A . Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence?. Mediterr J Rheumatol. 2020; 31(Suppl 2):259-267. PMC: 7656133. DOI: 10.31138/mjr.31.3.259. View

14.

Widge A, Rouphael N, Jackson L, Anderson E, Roberts P, Makhene M . Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med. 2020; 384(1):80-82. PMC: 7727324. DOI: 10.1056/NEJMc2032195. View

15.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

16.

. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. 2020; 80(4):527-538. PMC: 7712850. DOI: 10.1136/annrheumdis-2020-218310. View

17.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

18.

Rodriguez Y, Novelli L, Rojas M, De Santis M, Acosta-Ampudia Y, Monsalve D . Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun. 2020; 114:102506. PMC: 7296326. DOI: 10.1016/j.jaut.2020.102506. View

19.

Lopes Marques C, Kakehasi A, Pinheiro M, Mota L, Albuquerque C, Rocha Silva C . High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. RMD Open. 2021; 7(1). PMC: 7844930. DOI: 10.1136/rmdopen-2020-001461. View

20.

Strangfeld A, Schafer M, Gianfrancesco M, Lawson-Tovey S, Liew J, Ljung L . Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021; 80(7):930-942. PMC: 7843211. DOI: 10.1136/annrheumdis-2020-219498. View